Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Second line chemotherapy · 1 trial · 1 indication
Time to disease progression (TTP) in days was defined as the time from enrollment to objective disease progression (all categories other than objective disease progression was set to be censored including death before progression). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions. Tumor assessments were performed using computer tomography or magnetic resonance imaging. TTP as assessed by investigator, along with a recalculation done by computer algorithm is presented below. Median time was not assessed for 'Only Chemotherapy' group as randomization of participants was not feasible considering Trastuzumab widespread use in routine clinical practice.
| Arm | Type | Description |
|---|---|---|
| Trastuzumab + 2nd Line Chemotherapy | EXPERIMENTAL | - |
| Only Chemotherapy | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Second line chemotherapy | DRUG | As prescribed |
| trastuzumab [Herceptin] | DRUG | 6mg/kg iv every 3 weeks |
Inclusion Criteria: * female patients, \>= 18 years of age; * metastatic breast cancer; * HER2 overexpression (IHC 3+ and/or FISH positive); * disease progression during or after previous 1st line chemotherapy + Herceptin; * scheduled to receive 2nd line chemotherapy. Exclusion Criteria: * concur...
Top 20 of 92 competitors
Second line chemotherapy is used for treating Breast Cancer and Non-Squamous Non-Small Cell Lung Cancer. It is an oncology treatment developed by Roche Holding AG. The drug is currently in Phase 2 clinical development for these indications.
Second line chemotherapy is developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's effectiveness in treating certain types of cancer.
Second line chemotherapy is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied for its potential use in treating Breast Cancer and Non-Squamous Non-Small Cell Lung Cancer.
Second line chemotherapy has been studied in clinical trials including NCT00444587, a Phase 2 study of Herceptin in combination with 2nd-line chemotherapy in HER2 positive metastatic breast cancer patients, and NCT01328951, a Phase 3 study of erlotinib in advanced non-small cell lung cancer. Both trials are completed.
Second line chemotherapy is not the same as Herceptin. Herceptin is a specific drug used in combination with second-line chemotherapy in a clinical trial for HER2 positive metastatic breast cancer. Second line chemotherapy refers to the treatment regimen given after initial therapy has not worked.